1. Lazo PA. Functional implications of tetraspanin proteins in cancer biology. Cancer Sci. 2007; 98:1666–1677.
2. Stipp CS, Kolesnikova TV, Hemler ME. Functional domains in tetraspanin proteins. Trends Biochem Sci. 2003; 28:106–112.
3. Huang C, Taki T, Adachi M, Yagita M, Sawada S, Takabayashi A, et al. MRP-1/CD9 and KAI1/CD82 expression in normal and various cancer tissues. Int J Oncol. 1997; 11:1045–1051.
4. Miyake M, Nakano K, Itoi SI, Koh T, Taki T. Motility-related protein-1 (MRP-1/CD9) reduction as a factor of poor prognosis in breast cancer. Cancer Res. 1996; 56:1244–1249.
7. Kusukawa J, Ryu F, Kameyama T, Mekada E. Reduced expression of CD9 in oral squamous cell carcinoma: CD9 expression inversely related to high prevalence of lymph node metastasis. J Oral Pathol Med. 2001; 30:73–79.
8. Buim ME, Lourenço SV, Carvalho KC, Cardim R, Pereira C, Carvalho AL, et al. Downregulation of CD9 protein expression is associated with aggressive behavior of oral squamous cell carcinoma. Oral Oncol. 2010; 46:166–171.
9. Hori H, Yano S, Koufuji K, Takeda J, Shirouzu K. CD9 expression in gastric cancer and its significance. J Surg Res. 2004; 117:208–215.
10. Soyuer S, Soyuer I, Unal D, Ucar K, Yildiz OG, Orhan O. Prognostic significance of CD9 expression in locally advanced gastric cancer treated with surgery and adjuvant chemoradiotherapy. Pathol Res Pract. 2010; 206:607–610.
11. Huan J, Gao Y, Xu J, Sheng W, Zhu W, Zhang S, et al. Overexpression of CD9 correlates with tumor stage and lymph node metastasis in esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 2015; 8:3054–3061.
12. Kwon HJ, Min SY, Park MJ, Lee C, Park JH, Chae JY, et al. Expression of CD9 and CD82 in clear cell renal cell carcinoma and its clinical significance. Pathol Res Pract. 2014; 210:285–290.
![crossref](/image/icon/bnr_ref_cross.gif)
13. Kwon HJ, Choi JE, Kang SH, Son Y, Bae YK. Prognostic significance of CD9 expression differs between tumour cells and stromal immune cells, and depends on the molecular subtype of the invasive breast carcinoma. Histopathology. 2017; 70:1155–1165.
14. Lakhani SR, Rakha E, Simpson PT. Invasive lobular carcinoma. In : Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ, editors. WHO Classification of Tumors of the Breast. 4th ed. Lyon: IARC;2012. p. 40–42.
18. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013; 31:3997–4013.
19. Zöller M. Tetraspanins: push and pull in suppressing and promoting metastasis. Nat Rev Cancer. 2009; 9:40–55.
22. Kischel P, Bellahcene A, Deux B, Lamour V, Dobson R, DE Pauw E, et al. Overexpression of CD9 in human breast cancer cells promotes the development of bone metastases. Anticancer Res. 2012; 32:5211–5220.
23. Longo N, Yáñez-Mó M, Mittelbrunn M, de la Rosa G, Muñoz ML, Sánchez-Madrid F, et al. Regulatory role of tetraspanin CD9 in tumor-endothelial cell interaction during transendothelial invasion of melanoma cells. Blood. 2001; 98:3717–3726.
24. Kohmo S, Kijima T, Otani Y, Mori M, Minami T, Takahashi R, et al. Cell surface tetraspanin CD9 mediates chemoresistance in small cell lung cancer. Cancer Res. 2010; 70:8025–8035.